BG-T187 / BeOne Medicines - LARVOL DELTA

Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=87 | Recruiting | Sponsor: BeiGene | Trial completion date: Jan 2028 ➔ Sep 2028 | Trial primary completion date: Jan 2028 ➔ Sep 2028

Trial completion date • Trial primary completion date • Oncology • Solid Tumor

Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=87 | Recruiting | Sponsor: BeiGene | Active, not recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=87 | Active, not recruiting | Sponsor: BeiGene | Recruiting ➔ Active, not recruiting

Enrollment closed • Oncology • Solid Tumor

EGFR x MET tsAb: Differentiated MET biparatopic design with optimal MET inhibitory activity to pursue best-in-class opportunity (AACR 2025) - "Through a comprehensive assessment of EGFR on-target toxicity risk, we demonstrated that BG-T187 show better HEKn selectivity than EGFR/MET bi-specific antibody, indicating potential lower on-target toxicity risk of BG-T187. Collectively, our findings represent a novel EGFR/MET tri-specific antibody with differentiated MET biparatopic and pursue best-in-class potential."

Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • MET

Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=87 | Recruiting | Sponsor: BeiGene | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • Metastases • Trispecific • Oncology • Solid Tumor

Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=87 | Not yet recruiting | Sponsor: BeiGene

Combination therapy • Metastases • New P1 trial • Trispecific • Oncology • Solid Tumor